154 related articles for article (PubMed ID: 37290973)
1. A Birth Year Cohort and What It Can Reveal About Lipid Mediators as Putative Biomarkers of Progression in Multiple Sclerosis.
Rotstein D; Schneider R
Neurology; 2023 Aug; 101(5):197-198. PubMed ID: 37290973
[No Abstract] [Full Text] [Related]
2. Multiple sclerosis progression is not associated with birth timing in Italy.
Lucenti A; Galimberti S; Barizzone N; Naldi P; ; ; Comi G; Martinelli Boneschi F; D'Alfonso S; Leone MA
J Neurol Sci; 2014 Nov; 346(1-2):194-6. PubMed ID: 25194635
[TBL] [Abstract][Full Text] [Related]
3. Immunological surrogate markers of disease activity in multiple sclerosis.
Kieseier BC; Giovannoni G; Hartung HP
Electroencephalogr Clin Neurophysiol Suppl; 1999; 50():570-83. PubMed ID: 10689511
[No Abstract] [Full Text] [Related]
4. [Biomarkers in multiple sclerosis (a review and experimental data)].
Vorob'eva AA; Ivanova MV; Fominykh VV; Zakharova MN; Zigangirova NA; Guliaeva NV
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(10 Pt 2):23-31. PubMed ID: 24416809
[TBL] [Abstract][Full Text] [Related]
5. Multiple sclerosis: genetics, biomarkers, treatments.
Axisa PP; Hafler DA
Curr Opin Neurol; 2016 Jun; 29(3):345-53. PubMed ID: 27058221
[TBL] [Abstract][Full Text] [Related]
6. Genetic, Immune-Inflammatory, and Oxidative Stress Biomarkers as Predictors for Disability and Disease Progression in Multiple Sclerosis.
Kallaur AP; Reiche EMV; Oliveira SR; Simão ANC; Pereira WLCJ; Alfieri DF; Flauzino T; Proença CM; Lozovoy MAB; Kaimen-Maciel DR; Maes M
Mol Neurobiol; 2017 Jan; 54(1):31-44. PubMed ID: 26732588
[TBL] [Abstract][Full Text] [Related]
7. Serum NFL levels should be used to monitor multiple sclerosis evolution - No.
Myhr KM; Torkildsen Ø
Mult Scler; 2020 Jan; 26(1):19-21. PubMed ID: 31625829
[No Abstract] [Full Text] [Related]
8. Serum NFL levels should be used to monitor multiple sclerosis evolution - Commentary.
Chitnis T
Mult Scler; 2020 Jan; 26(1):21-22. PubMed ID: 31625830
[No Abstract] [Full Text] [Related]
9. Serum NfL levels should be used to monitor multiple sclerosis evolution - Yes.
Leppert D; Kuhle J
Mult Scler; 2020 Jan; 26(1):17-19. PubMed ID: 31625807
[No Abstract] [Full Text] [Related]
10. Combining biomarkers to profile multiple sclerosis patients.
Stefano N; Sormani MP
Nat Rev Neurol; 2020 Sep; 16(9):463-464. PubMed ID: 32555516
[No Abstract] [Full Text] [Related]
11. No prognostic value of routine cerebrospinal fluid biomarkers in a population-based cohort of 407 multiple sclerosis patients.
Becker M; Latarche C; Roman E; Debouverie M; Malaplate-Armand C; Guillemin F
BMC Neurol; 2015 May; 15():79. PubMed ID: 25966681
[TBL] [Abstract][Full Text] [Related]
12. Multiple sclerosis and magnetic resonance imaging: advancement in linking the pictures with the progression.
Racke MK; Hawker K; Frohman EM
Arch Neurol; 2001 Jan; 58(1):35-6. PubMed ID: 11176933
[No Abstract] [Full Text] [Related]
13. Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.
Raphael I; Webb J; Stuve O; Haskins W; Forsthuber T
Expert Rev Clin Immunol; 2015 Jan; 11(1):69-91. PubMed ID: 25523168
[TBL] [Abstract][Full Text] [Related]
14. Lipid profile of cerebrospinal fluid in multiple sclerosis patients: a potential tool for diagnosis.
Nogueras L; Gonzalo H; Jové M; Sol J; Gil-Sanchez A; Hervás JV; Valcheva P; Gonzalez-Mingot C; Solana MJ; Peralta S; Pamplona R; Brieva L
Sci Rep; 2019 Aug; 9(1):11313. PubMed ID: 31383928
[TBL] [Abstract][Full Text] [Related]
15. Peripheral blood biomarkers in multiple sclerosis.
D'Ambrosio A; Pontecorvo S; Colasanti T; Zamboni S; Francia A; Margutti P
Autoimmun Rev; 2015 Dec; 14(12):1097-110. PubMed ID: 26226413
[TBL] [Abstract][Full Text] [Related]
16. Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers.
Novakova L; Axelsson M; Malmeström C; Imberg H; Elias O; Zetterberg H; Nerman O; Lycke J
PLoS One; 2018; 13(4):e0194828. PubMed ID: 29614113
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the prognostic value of adipokines in multiple sclerosis.
Çoban A; Düzel B; Tüzün E; Tamam Y
Mult Scler Relat Disord; 2017 Jul; 15():11-14. PubMed ID: 28641765
[TBL] [Abstract][Full Text] [Related]
18. gMS-Classifier1 does not predict disability progression in multiple sclerosis.
van Rossum JA; Killestein J; Villar LM; Riskind PN; Freedman MS; Teunissen C
Mult Scler; 2019 Jun; 25(7):1010-1011. PubMed ID: 30168749
[No Abstract] [Full Text] [Related]
19. Comprehensive phenotyping in multiple sclerosis: discovery based proteomics and the current understanding of putative biomarkers.
O'Connor KC; Roy SM; Becker CH; Hafler DA; Kantor AB
Dis Markers; 2006; 22(4):213-25. PubMed ID: 17124343
[TBL] [Abstract][Full Text] [Related]
20. [Differential diagnosis of multiple sclerosis and systemic vasculitis].
Pizova NV
Zh Nevrol Psikhiatr Im S S Korsakova; 2004; 104(10):4-8. PubMed ID: 15553371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
